Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method.

In the last few years, there has been a boost in the use of cannabis-based extracts for medicinal purposes, although their preparation procedure has not been standardized but rather decided by the individual pharmacists. The present work describes the development of a simple and rapid high performance liquid chromatography method with UV detection (HPLC-UV) for the qualitative and quantitative determination of the principal cannabinoids (CBD-A, CBD, CBN, THC and THC-A) that could be applied to all cannabis-based medicinal extracts (CMEs) and easily performed by a pharmacist. In order to evaluate the identity and purity of the analytes, a high-resolution mass spectrometry (HPLC-ESI-QTOF) analysis was also carried out. Full method validation has been performed in terms of specificity, selectivity, linearity, recovery, dilution integrity and thermal stability. Moreover, the influence of the solvent (ethyl alcohol and olive oil) was evaluated on cannabinoids degradation rate. An alternative extraction method has then been proposed in order to preserve cannabis monoterpene component in final CMEs.

[1]  Ethan B. Russo Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects , 2011, British journal of pharmacology.

[2]  E. Carlini,et al.  Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. , 1974, European journal of pharmacology.

[3]  R. Jubb,et al.  PATIENTS AND METHODS , 1982 .

[4]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[5]  Kristian Linnet,et al.  Validation of a fully automated robotic setup for preparation of whole blood samples for LC-MS toxicology analysis. , 2012, Journal of analytical toxicology.

[6]  E. Heerdink,et al.  The prevalence and incidence of medicinal cannabis on prescription in The Netherlands , 2013, European Journal of Clinical Pharmacology.

[7]  D. Wade,et al.  A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms , 2003, Clinical rehabilitation.

[8]  J. McPartland,et al.  Cannabis is more than simply Δ9-tetrahydrocannabinol , 2003, Psychopharmacology.

[9]  T. Murphy,et al.  GC-MS analysis of the total delta9-THC content of both drug- and fiber-type cannabis seeds. , 2000, Journal of analytical toxicology.

[10]  D. Abrams,et al.  The Medicinal Use of Cannabis and Cannabinoids—An International Cross-Sectional Survey on Administration Forms , 2013, Journal of psychoactive drugs.

[11]  I. Yamamoto,et al.  Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis , 2008, Drug Metabolism and Disposition.

[12]  J. McPartland,et al.  Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? , 2001 .

[13]  Arno Hazekamp,et al.  Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine , 2013 .

[14]  J. Bronstein,et al.  Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders , 2014, Neurology.

[15]  B. Ludes,et al.  Determination of cannabinoids in whole blood by UPLC-MS-MS. , 2008, Journal of analytical toxicology.

[16]  S. Ferrara,et al.  Solid-phase extraction and HPLC-UV confirmation of drugs of abuse in urine. , 1992, Journal of analytical toxicology.

[17]  R. Sofia,et al.  Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats , 2004, Psychopharmacologia.

[18]  Peter M Fischer,et al.  Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and Δ(9)-tetrahydrocannabinol in rat plasma. , 2015, Journal of pharmaceutical and biomedical analysis.

[19]  Ethan B. Russo Cannabinoids in the management of difficult to treat pain , 2008, Therapeutics and clinical risk management.

[20]  S. A. Turkanis,et al.  The anticonvulsant activity of cannabidiol and cannabinol. , 1973, Life sciences.

[21]  K. Franson,et al.  The Pharmacologic and Clinical Effects of Medical Cannabis , 2013, Pharmacotherapy.

[22]  D. Wingard,et al.  High performance liquid chromatography with electrochemical detection. 1: Separation of Cannabis constituents and quantitation of Δ9 tetrahydrocannabinol , 1979 .

[23]  R. Verpoorte,et al.  Methods for the analysis of cannabinoids in biological materials: a review. , 2004, Phytochemical analysis : PCA.

[24]  J. Drewe,et al.  Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  B. Logan,et al.  Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs. , 2014, Forensic science review.

[26]  H. Wagner Synergy research: approaching a new generation of phytopharmaceuticals. , 2011, Fitoterapia.

[27]  K. Müller-Vahl,et al.  The therapeutic potential of cannabis and cannabinoids. , 2012, Deutsches Arzteblatt international.